Interferon in Early Multiple Sclerosis: The ETOMS Study

The recent CHAMPS study showed that interferon reduced the rate of conversion from early possible MS to definite MS (see JWN Dec 2000, p. 89, and N Engl J Med 2000; 343:898). Now, investigators from the Early Treatment of Multiple Sclerosis (ETOMS) trial -- a multicenter, manufacturer-sponsored, double-blind study -- report on the use of low-dose interferon beta-1a in a similar group of patients. A total of 308 patients with a first neurologic event suggestive of MS, an abnormal exam, and an abnormal MRI were randomized to receive either weekly, subcutaneous injections of interferon beta-1a (22 μg) or placebo. Follow-up lasted 2 years, during which time 78 percent of the randomized patients remained on treatment, and 90 percent remained in …